Amgen Inc.: clinical-trial pipeline
Amgen Inc. is the sponsor of 1,045 clinical trials in ClinicalTrials.gov and the EU CTIS portal; 114 are not yet finished and 8 were first posted in the last 90 days. Source: Arcadium Data, data as of .
Open trials114
Phase 2/3 and 3325
Countries68
New in 90 days8
Trials by phase
| Phase | Trials |
|---|---|
| Phase 3 | 320 |
| Phase 1 | 263 |
| Phase 2 | 241 |
| Not applicable | 88 |
| Phase 4 | 85 |
| Phase 1/2 | 41 |
| Phase 2/3 | 5 |
| Early phase 1 | 2 |
Trials by status
| Status | Trials |
|---|---|
| Completed | 794 |
| Terminated | 114 |
| Recruiting | 50 |
| Active, not recruiting | 46 |
| Not yet recruiting | 18 |
| Withdrawn or not authorised | 16 |
| Unknown | 4 |
| Suspended or halted | 3 |
Condition areas
| Area | Trials |
|---|---|
| Oncology | 360 |
| Immunology and rheumatology | 229 |
| Metabolic and endocrine (diabetes, obesity) | 133 |
| Nephrology and urology | 121 |
| Haematology | 111 |
| Cardiovascular | 108 |
| Dermatology | 102 |
| Musculoskeletal | 84 |
| Gastroenterology and liver | 46 |
| Rare and genetic diseases | 44 |
| Women's health and obstetrics | 43 |
| Neurology | 37 |
Countries
| Country | Trials |
|---|---|
| United States | 576 |
| Canada | 248 |
| Spain | 248 |
| Germany | 246 |
| France | 234 |
| Poland | 220 |
| Italy | 208 |
| Australia | 200 |
| Belgium | 195 |
| United Kingdom | 174 |
| Czechia | 157 |
| Hungary | 147 |
| Netherlands | 139 |
| Greece | 137 |
| Japan | 137 |
Latest changes
| Day | Change | Trial |
|---|---|---|
| 2026-10-13 | New trial posted | Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living Wi… |
| 2026-10-08 | New trial posted | Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes |
| 2026-10-01 | New trial posted | A Phase 3 Study of Inebilizumab in Participants With Primary Membranous Nephropathy |
| 2026-09-22 | New trial posted | Comparing the Extent to Which Two Maridebart Cafraglutide Drug Products Are Made Availabl… |
| 2026-09-21 | New trial posted | A Phase 3, Randomized, Double-Blind Extension Trial to Evaluate the Long-term Efficacy, S… |
| 2026-09-10 | New trial posted | Comparing the Extent to Which Romosozumab (AMG 785) is Made Available in the Body When Ad… |
| 2026-09-08 | New trial posted | A Phase 3, Open-Label, Multicenter, Randomized Study of Subcutaneous vs Intravenous Tarla… |
| 2026-09-04 | New trial posted | A Trial Assessing the Effectiveness of Evolocumab in Reducing the Plaque Burden in Partic… |
Open trials
The 25 most recently changed open trials.
| Registry id | Title | Phase | Status | Countries |
|---|---|---|---|---|
| NCT04540497 | A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease | Phase 3 | Active, not recruiting | Argentina, Australia, Canada, China +16 |
| NCT05284747 | EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction | Phase 4 | Active, not recruiting | Brazil, Sweden, United States |
| NCT04994717 | Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy… | Phase 3 | Active, not recruiting | Austria, Australia, Belgium, Bulgaria +27 |
| NCT03937154 | Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Can… | Phase 3 | Active, not recruiting | Argentina, Brazil, Spain, Greece +6 |
| NCT04524273 | Myasthenia Gravis Inebilizumab Trial | Phase 3 | Active, not recruiting | Argentina, Brazil, Belarus, Canada +14 |
| NCT05549258 | Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder | Phase 2 | Recruiting | Argentina, Brazil, Canada, Spain +7 |
| NCT04221542 | Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer | Phase 1 | Recruiting | Australia, Switzerland, China, Germany +6 |
| 2023-508359-38-00 | A Study Evaluating Pharmacokinetic similarity between ABP 234 and Keytruda® (pembrolizumab) in Subjects with… | Phase 3 | Active, not recruiting | Bulgaria, Germany, Spain, France +3 |
| NCT06211036 | Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lu… | Phase 3 | Active, not recruiting | Argentina, Austria, Australia, Belgium +25 |
| NCT06117774 | Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC) | Phase 3 | Not yet recruiting | Argentina, Austria, Australia, Belgium +22 |
| NCT03836040 | Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine | Phase 3 | Active, not recruiting | Belgium, Colombia, Germany, Spain +5 |
| NCT03319940 | Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung… | Phase 1 | Active, not recruiting | Austria, Australia, Switzerland, Germany +9 |
| NCT06333951 | Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homo… | Phase 1 | Active, not recruiting | Argentina, Austria, Australia, Belgium +15 |
| 2022-502352-31-00 | Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib, Panitumumab and FOLFIRI Ve… | Phase 3 | Recruiting | Austria, Belgium, Bulgaria, Czechia +14 |
| NCT05361395 | First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extens… | Phase 1 | Active, not recruiting | Australia, Belgium, Canada, Switzerland +11 |
| NCT06360354 | A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointes… | Phase 1 | Active, not recruiting | Australia, Belgium, Canada, China +12 |
| NCT04185883 | Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) | Phase 1 | Active, not recruiting | Austria, Australia, Belgium, Canada +9 |
| NCT06311721 | A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squa… | Phase 3 | Recruiting | Argentina, Austria, Bulgaria, Brazil +18 |
| NCT05060016 | A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC) | Phase 2 | Active, not recruiting | Austria, Belgium, Switzerland, Germany +14 |
| NCT06613100 | Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer | Phase 1 | Recruiting | Germany, United States |
| NCT06598306 | Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308) | Phase 1 | Recruiting | Australia, Belgium, Switzerland, China +5 |
| NCT06660173 | A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM) | Phase 2 | Active, not recruiting | Austria, Spain, Greece, Hong Kong SAR China +10 |
| NCT06321601 | Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Childre… | Phase 3 | Active, not recruiting | Belgium, Canada, Czechia, Spain +5 |
| NCT06248619 | A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adul… | Phase 3 | Not yet recruiting | Argentina, Australia, Canada, Germany +8 |
| NCT06700343 | Comparison Between ABP 692 and Ocrevus® (Ocrelizumab) | Phase 3 | Not yet recruiting | Belgium, Bulgaria, Canada, Switzerland +17 |
Hiring for clinical development
Amgen Inc. has 101 open jobs with a clinical, regulatory, safety, biostatistics or medical-affairs title on its own career sites: hiring profile of amgen.com.
Website: amgen.com. All sponsors: clinical-trial pipeline by sponsor.
Track a sponsor's pipeline
The API returns the same trials by sponsor website, phase, status, condition and country with a change feed, joined to hiring and public contract awards. Try it without a key on one sponsor.
Sources: ClinicalTrials.gov (U.S. National Library of Medicine, public domain) and the EU Clinical Trials Information System public portal (European Medicines Agency), data as of 2026-10-25. A trial that one register cites in the other is shown once. Organisation-level data only: investigators, contact persons and site names are not stored, and a sponsor that could be a private person is withheld. Sponsor-to-website matches are made by name and can be wrong; check the register before relying on a record. Independent of the NLM, NIH and EMA.
Cite as: Arcadium Data, "Amgen Inc. clinical trials: 114 open, 325 in phase 3", https://arcadiumdata.io/clinical-trials/sponsor/amgen-com/, data as of 2026-10-25.